{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:59:59Z","timestamp":1790175599313,"version":"4.1.0"},"reference-count":25,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>More than four decades after its discovery, p53 remains a central regulator of cellular homeostasis and one of the most extensively studied proteins in cancer biology [...]<\/jats:p>","DOI":"10.3390\/ijms27188233","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:58:59Z","timestamp":1789545539000},"page":"8233","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Issue \u201cp53\u2014Oncogene, Tumor Suppressor Gene, Guardian of the Genome and the Cell\u201d"],"prefix":"10.3390","volume":"27","author":[{"given":"Dennis","family":"Rangno","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8126-3686","authenticated-orcid":false,"given":"Przemyslaw","family":"Bozko","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"The M3 Research Center, Eberhard-Karls Universit\u00e4t T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/joim.20106","article-title":"The TP53 tumor suppressor gene: From molecular biology to clinical investigations","volume":"298","author":"Baliakas","year":"2025","journal-title":"J. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0898-6568(97)00119-8","article-title":"Multisite Phosphorylation and the integration of stress signals at p53","volume":"10","author":"Meek","year":"1998","journal-title":"Cell. Signal."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the Light: The Growing Complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"116332","DOI":"10.1016\/j.bcp.2024.116332","article-title":"P53: A key player in diverse cellular processes including nuclear stress and ribosome biogenesis, highlighting potential therapeutic compounds","volume":"226","author":"Temaj","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","article-title":"The multiple mechanisms that regulate p53 activity and cell fate","volume":"20","author":"Hafner","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41418-024-01326-1","article-title":"Determinants of p53 DNA binding, gene regulation, and cell fate decisions","volume":"31","author":"Fischer","year":"2024","journal-title":"Cell Death Differ."},{"key":"ref_8","first-page":"1136","article-title":"Mutant p53: The loaded gun","volume":"2","author":"Selivanova","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/ijmm.2024.5448","article-title":"TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)","volume":"55","author":"Tornesello","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/BCJ20240757","article-title":"Structure and function of MDM2 and MDM4 in health and disease","volume":"482","author":"Zhu","year":"2025","journal-title":"Biochem. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: One name, many proteins","volume":"26","author":"Prives","year":"2012","journal-title":"Genes Dev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","article-title":"Therapeutic targeting of p53: All mutants are equal, but some mutants are more equal than others","volume":"15","author":"Sabapathy","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1158\/2159-8290.CD-24-1638","article-title":"Mutant p53 Gain of Function: Why Many See It, Why Some Do Not","volume":"15","author":"Lozano","year":"2025","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Alvarado-Ortiz, E., de la Cruz-L\u00f3pez, K.G., Becerril-Rico, J., Sarabia-S\u00e1nchez, M.A., Ortiz-S\u00e1nchez, E., and Garc\u00eda-Carranc\u00e1, A. (2021). Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.607670"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in Context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41419-024-06783-7","article-title":"Canonical and non-canonical functions of p53 isoforms: Potentiating the complexity of tumor development and therapy resistance","volume":"15","author":"Guo","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/00006123-199911000-00016","article-title":"Adenovirus-mediated p53 gene therapy for human gliomas","volume":"45","author":"Lang","year":"1999","journal-title":"Neurosurgery"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2003.21.13.2508","article-title":"Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results","volume":"21","author":"Lang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101155","DOI":"10.1016\/j.gendis.2023.101155","article-title":"Twenty years of Gendicine\u00ae rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology","volume":"11","author":"Qi","year":"2024","journal-title":"Genes Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm1146","article-title":"Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors","volume":"10","author":"Issaeva","year":"2004","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: One protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","article-title":"Translating p53-based therapies for cancer into the clinic","volume":"24","author":"Peuget","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41571-023-00842-2","article-title":"Pharmacological reactivation of p53 in the era of precision anticancer medicine","volume":"21","author":"Tuval","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41392-025-02549-5","article-title":"p53: From understanding its structure to advances in therapeutic targeting","volume":"11","author":"Wang","year":"2026","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8233\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:03:39Z","timestamp":1790172219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":25,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188233"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188233","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}